

# Risk Assessment of Cnm-positive *S. mutans* in Stroke Survivors (RAMESSES) study

## Principal Investigator

**Masafumi Ihara**  
National Cerebral and Cardiovascular Center

## Summary

<b>Country</b>	Japan
<b>Principal Investigator</b>	Masafumi Ihara National Cerebral and Cardiovascular Center
<b>Contact person (email)</b>	Satoshi Hosoki
<b>Key publication/reference</b>	Hosoki S., Hattori Y., Saito, S., Takegami M., Tonomura S., Yamamoto Y., Ikeda S., Hosomi N., Oishi N., Morita Y., Miyamoto Y., Nomura R., Nakano K., Ihara M. Risk Assessment of Cnm-positive Streptococcus Mutans in Stroke Survivors (RAMESSES): Protocol for a Multicenter Prospective Cohort Study. <i>Front Neurol</i> 12;13:816147, 2022
<b>Years in which study conducted</b>	2018 – 2024
<b>Follow-up schedule</b>	2 years
<b>Sample</b>	
<b>Sample size (baseline sample)</b>	230
<b>Population:</b>	Hospital based
<b>Selection:</b>	Recent stroke/TIA
<b>Admit with previous stroke?</b>	Yes
<b>Admit with TIA?</b>	Yes
<b>Age range</b>	40+
<b>Number of centres</b>	3 or more

---

**Control group: number, population, selection**

NA

---

**Assessment**

<b>Assessment timings</b>	MoCa at baseline, 1 year and 2 years CDR at baseline and 2 years
<b>Functional tests</b>	Yes
<b>Neuropsychological/cognitive tests</b>	MoCA at baseline, 1 yr and 2 yr
<b>Dementia diagnosis</b>	CDR at baseline and at 2 years
<b>MRI scans (type e.g., T1-weighted; when and how many)</b>	FLAIR,DWI,MRA At baseline, after 1 year and after 2 years
<b>Genetics data (e.g., GWAS, APOE)</b>	No (but blood sample collected)
<b>Blood analysis</b>	Yes